Given the novel involvement of inositol polyphosphate multikinase in osteoclastogenesis and the possible therapeutic effect of curcumenol in regulating osteoporosis, inhibitors targeting inositol polyphosphate multikinase are likely to represent a novel direction for developing anti-osteoporosis medications. Here, IPMK is linked to osteoporosis.